Cover Image
市場調查報告書

老花眼治療藥的全球市場:開發平台分析,臨床實驗概況·結果,專利·指定·合作·其他趨勢

Presbyopia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations and Other Developments

出版商 P&S Market Research Pvt. Ltd 商品編碼 606434
出版日期 內容資訊 英文 77 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
老花眼治療藥的全球市場:開發平台分析,臨床實驗概況·結果,專利·指定·合作·其他趨勢 Presbyopia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations and Other Developments
出版日期: 2018年01月01日 內容資訊: 英文 77 Pages
簡介

本報告提供全球老花眼治療藥的市場相關分析,提供疾病概要和市場結構,主要的開發中產品概要和目前臨床實驗情形,主要的推動及阻礙市場要素,市場規模的實際成果值·預測值 (過去4年·今後7年份),各臨床實驗階段詳細趨勢,主要企業簡介等調查。

第1章 分析的背景情況

第2章 分析方法

第3章 摘要整理

第4章 開發中產品的展望

  • 疾病概要
    • 視力調整的理論
  • 流行病學
  • 老花眼的分類
  • 症狀
  • 老花眼的原因
  • 預後和後續行動
  • 治療方法
  • 主要的推動市場要素
  • 主要的阻礙市場要素
  • 老花眼治療藥的開發平台分析
    • 各期
    • 各分子類型
    • 各投藥途徑
    • 各企業

第5章 老花眼治療藥的開發平台分析:各期

  • 第一/二階段
    • 各產品的資訊 (臨床實驗概要/結果,策略趨勢)
  • 第二階段
    • Oxymetazoline Hydrochloride + Pilocarpine Hydrochloride
  • 第一階段
    • EV06 眼科用點劑
  • 前臨床
  • 藥物研發

第6章 臨床實驗概況

  • 各地區的情形
  • 各階段狀況

第7章 競爭環境

  • 老花眼治療藥的開發中產品:主要企業比較分析
  • 老花眼治療藥的開發中產品:SWOT分析

第8章 企業簡介

  • Allergan Plc.
    • 產業概要
    • 主要產品與服務
    • 企業發展/專利申請情形等
  • Novartis AG
  • 其他的企業

第9章 附錄

目錄

The study analyzed that the presbyopia therapeutics pipeline comprises nine drug candidates in different stages of development. Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as "an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock". Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a customary working distance without experiencing visual symptoms. The disease can result from the gradual decrease in the amplitude of accommodation.

Insights on pipeline segments

Various pharmaceutical companies such as Novartis AG, Allergan Plc., Janssen Global Services LLC, and Acucela Inc. are engaged in the development drug candidates for the treatment of presbyopia.

Positive clinical results of presbyopia drug candidates

Various pharmaceutical companies are developing drug candidates for the treatment of presbyopia, which have shown positive results in different stages of development. For instance, UNR844 showed a statistically significant difference to placebo in distant corrected near vision at all time points measured (from day 8) in the Phase I/II, placebo-controlled, proof-of-concept study carried out in 50 patients daily for 90 days with topical UNR844 and in 25 patients with placebo. At day 90, 82% of participants treated with UNR844 had 20/40 near vision (or 0.30 LogMAR) versus 48% in the placebo group. Near vision of 20/40 allows the majority of near vision tasks in most people.

Novel delivery systems and patented technologies for Presbyopia

Various pharmaceutical companies are involved in manufacturing drugs for the treatment of presbyopia. In January 2017, Alcon, the eye care division of Novartis AG, launched AcrySof IQ PanOptix Toric intraocular lens for presbyopia. The launch of the AcrySof IQ PanOptix Toric intraocular lens is a significant achievement in presbyopia treatment. Most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of presbyopia.

Some of the key players developing Novartis AG, Allergan Plc, and ORASIS Pharmaceuticals Ltd.

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope
    • 1.3.1 Pipeline Analysis by Phase
    • 1.3.2 Pipeline Analysis by Molecule Type
    • 1.3.3 Pipeline Analysis by Route of Administration
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By industry participant
      • 2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Disease Overview
    • 4.1.1 Theories of Accommodation
      • 4.1.1.1 The Helmholtz theory of accommodation
      • 4.1.1.2 The Schachar theory of accommodation
      • 4.1.1.3 The Coleman theory of accommodation
  • 4.2 Epidemiology
  • 4.3 Classification of Presbyopia
  • 4.4 Sign and Symptoms
  • 4.5 Etiology of Presbyopia
  • 4.6 Prognosis and Follow-up
  • 4.7 Treatment
  • 4.8 Key Drivers
    • 4.8.1 Driver 1
    • 4.8.2 Driver 2
  • 4.9 Key Barriers
    • 4.9.1 Barrier 1
    • 4.9.2 Barrier 2
  • 4.1 Presbyopia Therapeutics Pipeline Analysis
    • 4.10.1 Pipeline Analysis by Phase
    • 4.10.2 Pipeline Analysis by Molecule Type
    • 4.10.3 Pipeline Analysis by Route of Administration
    • 4.10.4 Pipeline Analysis by Company

Chapter 5. Presbyopia Therapeutics Pipeline Analysis by Phase (2018)

  • 5.1 Phase II/III
    • 5.1.1 XXXX
      • 5.1.1.1 Clinical trials
      • 5.1.1.2 Clinical trial results
  • 5.2 Phase II
    • 5.2.1 Oxymetazoline Hydrochloride + Pilocarpine Hydrochloride
      • 5.2.1.1 Clinical trials
      • 5.2.1.2 Clinical trial results
      • 5.2.1.3 Strategic developments
    • 5.2.2 XXXX
      • 5.2.2.1 Clinical trials
      • 5.2.2.2 Clinical trial results
    • 5.2.3 XXXX
      • 5.2.3.1 Clinical trials
      • 5.2.3.2 Clinical trial results
    • 5.2.4 XXX
      • 5.2.4.1 Clinical trials
      • 5.2.4.2 Clinical trial results
      • 5.2.4.3 Patents
  • 5.3 Phase I
    • 5.3.1 EV06 Ophthalmic Solution
      • 5.3.1.1 Clinical trials
      • 5.3.1.2 Clinical trial results
      • 5.3.1.3 Strategic developments
  • 5.4 Pre-Clinical
    • 5.4.1 VP1-001
      • 5.4.1.1 Strategic developments
    • 5.4.2 XXXX
  • 5.5 Discovery
    • 5.5.1 XXXX
      • 5.5.1.1 Strategic developments

Chapter 6. Clinical Trials Review

  • 6.1 Clinical Trials by Region
  • 6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for Presbyopia Therapeutics Pipeline
  • 7.2 SWOT Analysis of Presbyopia Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Allergan Plc.
    • 8.1.1 Business Overview
    • 8.1.2 Product and Service Offerings
  • 8.2 Novartis AG
    • 8.2.1 Business Overview
    • 8.2.2 Product and Service Offerings
  • 8.3 XXXX
    • 8.3.1 Business Overview
    • 8.3.2 Product and Service Offerings
  • 8.4 XXXX
    • 8.4.1 Business Overview
    • 8.4.2 Product and Service Offerings
  • 8.5 XXXX
    • 8.5.1 Business Overview
    • 8.5.2 Product and Service Offerings
  • 8.6 XXXX
    • 8.6.1 Business Overview
    • 8.6.2 Product and Service Offerings
  • 8.7 XXXX
    • 8.7.1 Business Overview
    • 8.7.2 Product and Service Offerings

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.1 Related Reports

LIST OF TABLES

  • TABLE 1: PIPELINE ANALYSIS OF PRESBYOPIA THERAPEUTICS, BY COMPANY (2018)
  • TABLE 2: DESCRIPTION OF XXXX
  • TABLE 3: CLINICAL TRIALS OF XXXX
  • TABLE 4: DESCRIPTION OF (OXYMETAZOLINE HYDROCHLORIDE + PILOCARPINE HYDROCHLORIDE)
  • TABLE 5: CLINICAL TRIALS OF (OXYMETAZOLINE HYDROCHLORIDE + PILOCARPINE HYDROCHLORIDE)
  • TABLE 6: DESCRIPTION OF XXXX
  • TABLE 7: CLINICAL TRIALS OF XXXX
  • TABLE 8: DESCRIPTION OF XXXX
  • TABLE 9: CLINICAL TRIALS OF XXXX
  • TABLE 10: DESCRIPTION OF XXXX
  • TABLE 11: CLINICAL TRIALS OF XXXX
  • TABLE 12: DESCRIPTION OF EV06 OPHTHALMIC SOLUTION
  • TABLE 13: CLINICAL TRIALS OF EV06 OPHTHALMIC SOLUTION
  • TABLE 14: DESCRIPTION OF VP1-001
  • TABLE 15: DESCRIPTION OF XXXX
  • TABLE 16: DESCRIPTION OF XXXX
  • TABLE 17: ALLERGAN PLC. - AT A GLANCE
  • TABLE 18: NOVARTIS AG - AT A GLANCE
  • TABLE 19: XXXX - AT A GLANCE
  • TABLE 20: XXXX - AT A GLANCE
  • TABLE 21: XXXX - AT A GLANCE
  • TABLE 22: XXXX - AT A GLANCE
  • TABLE 23: XXXX - AT A GLANCE

LIST OF FIGURES

  • FIG 1: RESEARCH METHODOLOGY
  • FIG 2: SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
  • FIG 4: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE
  • FIG 5: PRESBYOPIA IN HUMAN EYE
  • FIG 6: APPLICATION OF THE HELMHOLTZ THEORY OF ACCOMMODATION IN PRESBYOPIA
  • FIG 7: APPLICATION OF THE SCHACHAR THEORY OF ACCOMMODATION IN PRESBYOPIA
  • FIG 8: APPLICATION OF THE COLEMAN THEORY OF ACCOMMODATION IN PRESBYOPIA
  • FIG 9: PRESBYOPIC SURGICAL METHODS
  • FIG 10: PRESBYOPIA DRUG CANDIDATES UNDER DEVELOPMENT (2018)
  • FIG 11: PRESBYOPIA PIPELINE SPLIT, BY MOLECULE TYPE (2018)
  • FIG 12: BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • FIG 13: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • FIG 14: KEY PLAYERS BENCHMARKING
  • FIG 15: SWOT ANALYSIS
Back to Top